A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Summary

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Timeline

Start

2023-06-12

Primary completion

2024-12-30

Completion

2025-11-04

Outcome

Missed primary endpoint

registry analysis (superiority test); Vehicle Cream BID to Ruxolitinib 1.5% Cream BID vs Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID; p = 0.5859 NCT05764161 ↗

release “Topline data from a separate Phase 3 study, TRuE-PN2, showed that while the primary endpoint did not reach statistical significance” incyte.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	1.5 %	Topical

Indications